ArticleNature cancer2021

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.

Melissa B Pappalardi et al.PubMed ↗Full text ↗

No numbers read from the abstract.